{
  "patient_id": "SyntheticDemo_001",
  "case_type": "synthetic_demo",
  "complexity_level": "moderate",
  "created_date": "2025-11-26",
  "purpose": "RLHF demonstration - end-to-end pipeline validation",

  "ground_truth_diagnosis": {
    "primary_diagnosis": {
      "condition": "Dravet Syndrome",
      "omim": "607208",
      "orpha": "33069",
      "icd10": "G40.409",
      "confidence": "definitive",
      "causative_gene": "SCN1A",
      "causative_variant": "c.4933C>T (p.Arg1645Ter)",
      "inheritance": "de_novo"
    },
    "secondary_findings": [
      {
        "condition": "GABRA1 variant of uncertain significance",
        "clinical_relevance": "possible_modifier",
        "requires_followup": true,
        "notes": "May contribute to seizure severity or represent genetic background variation"
      }
    ]
  },

  "expected_differential_diagnosis": {
    "rank_1": {
      "diagnosis": "Dravet Syndrome",
      "gene": "SCN1A",
      "expected_confidence": 0.95,
      "key_supporting_features": [
        "Prolonged febrile seizures in infancy",
        "Multiple seizure types",
        "Developmental regression",
        "Photosensitivity",
        "Worsening with sodium channel blockers",
        "De novo truncating SCN1A variant"
      ]
    },
    "rank_2": {
      "diagnosis": "SCN1A-negative Dravet-like syndrome",
      "gene": "Multiple (SCN1B, SCN2A, GABRA1, GABRG2, PCDH19)",
      "expected_confidence": 0.03,
      "notes": "Would be considered if SCN1A testing was negative"
    },
    "rank_3": {
      "diagnosis": "GABRA1-related epileptic encephalopathy",
      "gene": "GABRA1",
      "expected_confidence": 0.01,
      "notes": "GABRA1 variant present but likely not primary cause given inheritance pattern"
    },
    "rank_4": {
      "diagnosis": "Other genetic epileptic encephalopathy",
      "gene": "Various",
      "expected_confidence": 0.01,
      "notes": "Broad category for remaining probability"
    }
  },

  "expected_variant_classifications": {
    "SCN1A_c.4933C>T": {
      "expected_classification": "Pathogenic",
      "expected_acmg_criteria": ["PVS1", "PS2", "PM2", "PP3", "PP4"],
      "is_causative": true,
      "notes": "Truncating variant in haploinsufficiency gene with de novo status"
    },
    "SCN9A_c.2215G>A": {
      "expected_classification": "Likely Benign",
      "expected_acmg_criteria": ["BS1", "BP4"],
      "is_causative": false,
      "notes": "Population frequency and computational evidence argue against pathogenicity"
    },
    "GABRA1_c.641G>A": {
      "expected_classification": "VUS",
      "expected_acmg_criteria": ["PM2", "PP3", "BS4"],
      "is_causative": false,
      "notes": "Rare variant but inherited from unaffected father"
    }
  },

  "expected_tool_outputs": {
    "clinvar": {
      "SCN1A_c.4933C>T": "Pathogenic (2 stars)",
      "GABRA1_c.641G>A": "VUS (1 star)"
    },
    "alphamissense": {
      "GABRA1_c.641G>A": 0.72,
      "SCN9A_c.2215G>A": 0.28
    },
    "spliceai": {
      "all_variants": "No significant splicing impact (max delta < 0.1)"
    },
    "revel": {
      "GABRA1_c.641G>A": 0.68,
      "SCN9A_c.2215G>A": 0.32
    }
  },

  "expected_recommendations": [
    {
      "category": "treatment",
      "recommendation": "Avoid sodium channel blocker antiepileptic drugs (carbamazepine, lamotrigine, phenytoin)",
      "priority": "high"
    },
    {
      "category": "treatment",
      "recommendation": "Continue current Dravet-appropriate regimen (valproate, clobazam, stiripentol)",
      "priority": "high"
    },
    {
      "category": "treatment",
      "recommendation": "Consider adding fenfluramine if seizures remain uncontrolled",
      "priority": "medium"
    },
    {
      "category": "monitoring",
      "recommendation": "SUDEP risk counseling and seizure monitoring",
      "priority": "high"
    },
    {
      "category": "genetic_counseling",
      "recommendation": "Counsel family on de novo inheritance and low recurrence risk",
      "priority": "medium"
    },
    {
      "category": "support",
      "recommendation": "Refer to Dravet Syndrome Foundation for resources",
      "priority": "medium"
    }
  ],

  "evaluation_criteria": {
    "diagnosis_accuracy": {
      "weight": 0.35,
      "rubric": {
        "excellent": "Dravet syndrome ranked first with high confidence, SCN1A identified as causative",
        "good": "Dravet syndrome in top 2, genetic epileptic encephalopathy considered",
        "acceptable": "Correct gene family identified (sodium channels)",
        "poor": "Missed SCN1A or misclassified as benign condition"
      }
    },
    "variant_classification": {
      "weight": 0.25,
      "rubric": {
        "excellent": "All three variants correctly classified per ACMG guidelines",
        "good": "SCN1A correctly classified as pathogenic, others reasonable",
        "acceptable": "Primary variant identified but classification criteria incomplete",
        "poor": "SCN1A misclassified or causative variant missed"
      }
    },
    "treatment_recommendations": {
      "weight": 0.25,
      "rubric": {
        "excellent": "All key recommendations present, drug avoidance emphasized",
        "good": "Sodium channel blocker avoidance mentioned, appropriate medications listed",
        "acceptable": "Some relevant recommendations but incomplete",
        "poor": "Missing critical safety information (drug avoidance)"
      }
    },
    "completeness": {
      "weight": 0.15,
      "rubric": {
        "excellent": "All sections complete with supporting evidence cited",
        "good": "Major sections complete, minor gaps",
        "acceptable": "Core diagnosis present but limited detail",
        "poor": "Significant missing information"
      }
    }
  },

  "metadata": {
    "source": "synthetic",
    "inspired_by": "Composite of published Dravet syndrome cases",
    "references": [
      "Dravet C. (2011). Dravet syndrome history. Dev Med Child Neurol. 53 Suppl 2:1-6.",
      "Wirrell EC, et al. (2022). International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 63(7):1761-1777.",
      "Claes L, et al. (2001). De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 68(6):1327-32."
    ]
  }
}
